U.S. Luxury Stock News

During the fourth quarter of 2025, Baker Bros. Advisors increased its Kodiak Sciences stake by 2,608,696 shares, an estimated US$53.42 million investment, while the company’s lead retinal drug candidates tarcocimab and KSI-501 continued Phase 3 trials targeting the anti-VEGF market. This combination of heightened institutional interest and late-stage clinical progress positions Kodiak Sciences at a pivotal moment in its attempt to compete in a roughly US$15 billion retinal therapy...

Clarivate (CLVT) has rounded out FY 2025 with Q4 revenue of US$617 million and basic EPS of US$0.00, translating into net income of US$3.1 million. Over the past six quarters, the company has seen quarterly revenue move between US$593.7 million and US$663 million while basic EPS ranged from a loss of US$0.27 to the Q4 FY 2025 level, as net income swung between a loss of US$191.8 million and a small profit. For investors, the key question now is whether this earnings profile can support...

Orthofix Medical (OFIX) has just posted its FY 2025 fourth quarter scorecard, reporting revenue of US$219.9 million and a basic EPS loss of US$0.06. Trailing 12 month revenue stands at US$822.3 million against a net loss of US$92.2 million. Over the past few quarters, the company has reported revenue increasing from US$193.6 million in Q1 2025 to US$219.9 million in Q4 2025, while basic EPS losses narrowed from US$1.35 to US$0.06. This outlines an earnings story that remains marked by...

Helix Energy Solutions Group (HLX) has wrapped up FY 2025 with fourth quarter revenue of US$334.2 million and basic EPS of US$0.06, alongside net income of US$8.3 million. On a trailing twelve month basis the company generated US$1.3 billion of revenue and EPS of US$0.21 from net income of US$30.8 million. Over the last few quarters the business has seen revenue move between US$278.1 million and US$377.0 million, with quarterly EPS ranging from a small loss of about US$0.02 to a recent high...

Interface (TILE) closed out FY 2025 with Q4 revenue of US$349.4 million and basic EPS of US$0.42, while trailing twelve month EPS reached US$1.99 on revenue of about US$1.4 billion, setting a clear earnings and sales backdrop for investors. Over the past few quarters, the company has seen revenue move from US$335.0 million in Q4 2024 to US$375.5 million in Q2 2025 and then to US$349.4 million in Q4 2025, with basic EPS ranging from US$0.22 in Q1 2025 to US$0.79 in Q3 2025, giving a view of...

Backblaze FY 2025 Earnings Snapshot Backblaze (BLZE) has closed out FY 2025 with Q4 revenue of US$37.8 million and a basic EPS loss of US$0.09, while the trailing twelve months show revenue of US$145.8 million and a basic EPS loss of US$0.46, keeping the focus squarely on the path toward profitability. The company has seen quarterly revenue move from US$32.6 million in Q3 FY 2024 to US$37.8 million in Q4 FY 2025, with basic EPS losses narrowing from US$0.29 to US$0.09 over the same span as...

Quaker Chemical (KWR) closed out FY 2025 with Q4 revenue of US$468.5 million and basic EPS of US$1.20, alongside net income of US$20.8 million. Over the last few quarters, the company has seen revenue move from US$444.1 million and EPS of US$0.80 in Q4 2024 to a high of US$493.8 million and EPS of US$1.75 in Q3 2025, before landing at the latest Q4 figures. Trailing twelve month EPS sat at a slight loss of US$0.14 on revenue of about US$1.9 billion. For investors, this set of results puts the...

Innovex International (INVX) just posted its FY 2025 numbers, with Q4 revenue of US$273.6 million and basic EPS of US$0.20. This sets the tone for a year where trailing twelve month revenue reached US$978.3 million and EPS came in at US$1.21, as earnings growth over the last 12 months turned negative compared to earlier periods. The company has seen revenue move from US$660.8 million and EPS of US$2.82 on a trailing basis in FY 2024 to the latest trailing figures. These now sit alongside a...

Bed Bath & Beyond (BBBY) has reported FY 2025 fourth quarter revenue of US$273.4 million with a basic EPS loss of US$0.30, alongside trailing twelve month revenue of US$1.0 billion and a basic EPS loss of US$1.41. The company has seen quarterly revenue move from US$303.2 million in Q4 2024 to US$231.7 million in Q1 2025, US$282.3 million in Q2, US$257.2 million in Q3 and US$273.4 million in Q4, while quarterly basic EPS losses ranged from US$1.66 a share in Q4 2024 to US$0.74, US$0.34,...

Xometry (XMTR) has wrapped up FY 2025 with Q4 revenue of US$192.4 million and a basic EPS loss of US$0.17, alongside net income excluding extra items of a US$8.6 million loss. The company has seen revenue move from US$148.5 million in Q4 2024 to US$192.4 million in Q4 2025, while quarterly basic EPS shifted from a loss of US$0.20 to a loss of US$0.17. This sets up a results season in which investors will focus squarely on how quickly margins can tighten toward profitability. See our full...

Westlake Chemical Partners (WLKP) has wrapped up FY 2025 with Q4 revenue of US$323.0 million and EPS of US$0.41, with trailing twelve month revenue at US$1.2 billion and EPS of US$1.38 framing the latest numbers. The company has seen quarterly revenue range from US$237.6 million to US$323.0 million over the year while EPS moved from US$0.14 in Q1 2025 to around US$0.41 in each of the last three quarters, setting up a picture where net margin compression and softer earnings trends are key...

Apellis Pharmaceuticals (APLS) capped FY 2025 with Q4 revenue of US$199.9 million and basic EPS of US$0.47 loss, alongside a net loss of US$59.0 million. On a trailing twelve month basis, the company booked revenue of US$1.0 billion and basic EPS of US$0.18 profit. Over the past year, revenue has moved from US$781.4 million to US$1.0 billion on a trailing basis, with EPS shifting from a loss of US$1.60 to a profit of US$0.18. This sets up a story where investors may weigh sustained revenue...

Haverty Furniture Companies posts steady FY 2025 finish with higher Q4 earnings Haverty Furniture Companies (HVT) has wrapped up FY 2025 with Q4 revenue of US$201.9 million and basic EPS of US$0.52, alongside net income of US$8.5 million, setting a clear marker for how the year closed. The company has seen quarterly revenue move from US$175.9 million in Q3 FY 2024 to US$201.9 million in Q4 FY 2025, while basic EPS shifted from US$0.30 to US$0.52 over the same stretch, giving investors a...

HealthStream (HSTM) closed out FY 2025 with Q4 revenue of US$79.7 million and basic EPS of US$0.09, alongside trailing 12 month revenue of US$304.1 million and EPS of US$0.61 that frame the latest quarter in a broader earnings context. Over recent periods, the company has seen revenue move from US$291.6 million on a trailing basis after Q4 2024 to US$304.1 million after Q4 2025, while trailing EPS shifted from US$0.66 to US$0.61, setting up a picture where earnings forecasts and valuation...

Erie Indemnity (ERIE) closed out FY 2025 with fourth quarter revenue of US$951.0 million and basic EPS of US$1.21, while trailing twelve month revenue stood at about US$4.1 billion and EPS at US$10.70. Together, these figures set the scene for a year in which margins and earnings quality will be front of mind for investors. The company has seen quarterly revenue move from US$924.1 million and EPS of US$3.29 in Q4 2024 to US$951.0 million and EPS of US$1.21 in Q4 2025. Those shifts, alongside...

If you are trying to figure out whether RXO is attractively priced right now, it helps to separate the share price story from the underlying valuation story. RXO closed at US$14.84 recently, with a small 0.1% move over the last week, a 4.6% decline over the past month, a 15.6% gain year to date, and a 25.5% decline over the past year. Recent price moves have put RXO back on the radar as investors reassess transportation and logistics names in light of sector specific news flow and changing...

Diversified Healthcare Trust (DHC) closed FY 2025 with Q4 revenue of US$379.6 million and a basic EPS loss of US$0.09, while trailing twelve month revenue came in at about US$1.5 billion with a basic EPS loss of US$1.19. The company has seen quarterly revenue hold in a tight band between US$373.6 million and US$388.7 million from Q3 2024 through Q4 2025, alongside basic EPS results ranging from a US$0.04 loss to a US$0.68 loss per quarter. This sets the scene for investors to focus closely on...

ACV Auctions (ACVA) has wrapped up FY 2025 with Q4 revenue of US$183.6 million and a basic EPS loss of US$0.11, while trailing twelve month revenue came in at US$759.6 million with a basic EPS loss of US$0.39. The company has seen revenue move from US$159.5 million in Q4 2024 to US$183.6 million in Q4 2025, with quarterly EPS losses ranging between US$0.04 and US$0.16 over the past six reported quarters. This sets the stage for investors to focus on how quickly those losses might narrow...

Novanta (NOVT) has wrapped up FY 2025 with fourth quarter revenue of US$258.3 million and basic EPS of US$0.46, alongside net income of US$17.5 million, setting the tone for how investors will read its latest earnings update. The company has seen quarterly revenue move from US$238.1 million and EPS of US$0.46 in Q4 2024 to US$258.3 million and EPS of US$0.46 in Q4 2025. Trailing twelve month net income of US$53.8 million on revenue of US$980.6 million provides the broader backdrop. With net...

Tutor Perini (NYSE:TPC) reports strong operational recovery with better cash flow and margin performance. The company posts a sharp improvement in quarterly EPS growth alongside healthier free cash flow. These operational shifts point to a business that is running more efficiently and generating stronger results from existing projects. Tutor Perini’s recent progress comes with the stock trading at $85.87, after a 4.4% gain over the past week and 13.0% over the past month. The move adds to a...

EverQuote (EVER) just wrapped up FY 2025 with fourth quarter revenue of US$195.3 million and basic EPS of US$1.60, alongside net income of US$57.8 million, setting a clear headline for its latest results. The company has seen revenue move from US$147.5 million and EPS of US$0.35 in Q4 2024 to US$195.3 million and EPS of US$1.60 in Q4 2025, with trailing twelve month revenue at US$692.5 million and EPS at US$2.75 giving investors a fuller view of the earnings run rate. Taken together with a...

Bowhead Specialty Holdings (BOW) just wrapped up FY 2025 with Q4 total revenue of US$151.7 million and basic EPS of US$0.40, alongside trailing 12 month revenue of US$551.6 million and EPS of US$1.59 that sit against a one year earnings increase of 40.6%. Over recent quarters the company has seen revenue move from US$119.3 million in Q4 2024 to US$151.7 million in Q4 2025, while basic EPS shifted from US$0.42 to US$0.40. This sets up a picture where margins and profit efficiency are firmly in...

UFP Industries (UFPI) has wrapped up FY 2025 with fourth quarter revenue of US$1.3 billion and EPS of US$0.70, while trailing 12 month figures show revenue of US$6.3 billion and EPS of US$5.00, giving investors a clear read on both the quarter and the year as a whole. Over recent quarters the company has seen revenue move from US$1.6 billion in Q1 2025 to US$1.8 billion in Q2 2025 and US$1.6 billion in Q3 2025 before landing at US$1.3 billion in Q4. EPS shifted from US$1.30 to US$1.70,...

Avidity Biosciences (RNA) has wrapped up FY 2025 with fourth quarter revenue of about US$0.9 million, a basic EPS loss of US$1.54 and a net loss of roughly US$237.1 million. Over recent quarters the company has seen revenue move from US$2.3 million in Q3 2024 to US$12.5 million in Q3 2025. Basic EPS shifted from a loss of US$0.65 in Q3 2024 to a loss of US$1.27 in Q3 2025, and trailing 12 month EPS landed at a loss of US$4.97. This sets the stage for a results season where investors are...